Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.

Yoshimasa AsoYoshihisa TakadaKen TomotsuneYasuko ChibaMihoko MatsumuraTeruo JojimaMinoru SatoNobuya FujitaHisamoto KurodaShunichi MuranoIsao Usui

Published in: International journal of clinical practice (2020)

In patients with inadequately controlled type 2 diabetes on insulin therapy and oral antidiabetic drugs, treatment with the once-daily dual injection of IDeg + Lira compared with the twice-daily single injection of IDegAsp showed no significant difference in glycaemic control but statistically superior weight loss.

Keyphrases

type diabetes
glycemic control
weight loss
physical activity
cardiovascular disease
insulin resistance
bariatric surgery
ultrasound guided
study protocol
stem cells
roux en y gastric bypass
metabolic syndrome
open label
combination therapy
drug induced